Literature DB >> 18047389

Economic evidence at the local level : options for making it more useful.

Kees van Gool1, Gisselle Gallego, Marion Haas, Rosalie Viney, Jane Hall, Robyn Ward.   

Abstract

Like other countries, Australia has had some success in incorporating economic evidence into national healthcare decisions. However, it has been recognised that this coverage does not extend to the local hospital or health region level. An extensive body of research has identified barriers to the use of economic evidence at the local level, leading some commentators to suggest that economic evaluation should only be targeted at national decision-making bodies. Yet, local decision makers in Australia and elsewhere make important choices about the uptake and diffusion of healthcare technologies. We propose a number of interrelated options to address the barriers that currently prohibit the use of economic evaluation by local decision makers in many jurisdictions. These include wider dissemination of user friendly models, inclusion of assessments of the cost impact of interventions on various budgets, and the establishment of an authoritative body that ensures the production of high quality economic models. It is argued that these options can have a significant impact on the way economic evaluations are conducted, reported, disseminated and used.

Mesh:

Year:  2007        PMID: 18047389     DOI: 10.2165/00019053-200725120-00006

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  31 in total

1.  Pharmacoeconomics and clinical practice guidelines. A survey of attitudes in Swedish formulary committees.

Authors:  A Anell; P Svarvar
Journal:  Pharmacoeconomics       Date:  2000-02       Impact factor: 4.981

2.  Technology as a 'major driver' of health care costs: a cointegration analysis of the Newhouse conjecture.

Authors:  Albert A Okunad; Vasudeva N R Murthy
Journal:  J Health Econ       Date:  2002-01       Impact factor: 3.883

3.  Are decisions by purchasers in an English health district evidence-based?

Authors:  Paul Johnstone; Prabha Lacey
Journal:  J Health Serv Res Policy       Date:  2002-07

Review 4.  Is economic evaluation in touch with society's health values?

Authors:  Joanna Coast
Journal:  BMJ       Date:  2004-11-20

5.  End-user involvement in health technology assessment (HTA) development: a way to increase impact.

Authors:  Maurice McGregor; James M Brophy
Journal:  Int J Technol Assess Health Care       Date:  2005       Impact factor: 2.188

6.  The value of medical spending in the United States, 1960-2000.

Authors:  David M Cutler; Allison B Rosen; Sandeep Vijan
Journal:  N Engl J Med       Date:  2006-08-31       Impact factor: 91.245

7.  Linking evidence from health technology assessments to policy and decision making: the Alberta model.

Authors:  Henry Z Borowski; Jon Brehaut; David Hailey
Journal:  Int J Technol Assess Health Care       Date:  2007       Impact factor: 2.188

Review 8.  Developing guidance for budget impact analysis.

Authors:  P Trueman; M Drummond; J Hutton
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

9.  A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68).

Authors:  P M Clarke; A M Gray; A Briggs; A J Farmer; P Fenn; R J Stevens; D R Matthews; I M Stratton; R R Holman
Journal:  Diabetologia       Date:  2004-10-27       Impact factor: 10.122

Review 10.  The credibility of health economic models for health policy decision-making: the case of population screening for abdominal aortic aneurysm.

Authors:  Helen Campbell; Andrew Briggs; Martin Buxton; Lois Kim; Simon Thompson
Journal:  J Health Serv Res Policy       Date:  2007-01
View more
  5 in total

1.  Hospital drug and therapeutics committees in Australia: is there a role for economic evaluation at the institutional level?

Authors:  Gisselle Gallego
Journal:  Int J Clin Pharm       Date:  2011-12

2.  Resource modelling: the missing piece of the HTA jigsaw?

Authors:  Praveen Thokala; Simon Dixon; Beate Jahn
Journal:  Pharmacoeconomics       Date:  2015-03       Impact factor: 4.981

3.  Management of Hospital Formularies in Ontario: Challenges within a Local Health Integration Network.

Authors:  Natasha Burke; James M Bowen; Sue Troyan; Jathishinie Jegathisawaran; Carolyn Gosse; Marita Tonkin; Sandra Kagoma; Ron Goeree; Anne Holbrook
Journal:  Can J Hosp Pharm       Date:  2016-06-30

4.  Pharmacoeconomic analysis in Saudi Arabia: an overdue agenda item for action.

Authors:  Abdulrazaq S Al-Jazairi; Nada S Al-Qadheeb; Aziza Ajlan
Journal:  Ann Saudi Med       Date:  2011 Jul-Aug       Impact factor: 1.526

5.  Stakeholder engagement in economic evaluation: Protocol for using the nominal group technique to elicit patient, healthcare provider, and health system stakeholder input in the development of an early economic evaluation model of chimeric antigen receptor T-cell therapy.

Authors:  Kednapa Thavorn; Justin Presseau; Mackenzie Wilson; Terry Hawrysh; Ian D Graham; Harold Atkins; Natasha Kekre; Doug Coyle; Manoj M Lalu; Dean A Fergusson; Kelvin Kw Chan; Daniel A Ollendorf
Journal:  BMJ Open       Date:  2021-08-12       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.